Preferred Name |
Doxylamine |
|
Synonyms |
DOXYLAMINE Doxylamine |
|
Definitions |
A first generation ethanolamine with antiinflammatory, sedative and antihistamine properties. Doxylamine competitively inhibits the histamine 1 (H1) receptor, thereby preventing the action of endogenous histamine as well as the subsequent release of pro-inflammatory mediators from basophils and mast cells. This agent acts as an inverse agonist that combines with, and stabilizes the inactive form of the H1-receptor, shifting the H1 receptor equilibrium toward the inactive state. This results in downregulation of nuclear factor-kappaB (NF-kappaB) and NF-kappaB dependent antigen presentation, chemotaxis, as well as expression of cell-adhesion molecules and pro-inflammatory cytokines. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61738 |
|
CAS_Registry |
469-21-6 |
|
CHEBI_ID |
CHEBI:51380 |
|
Chemical_Formula |
C17H22N2O |
|
code |
C61738 |
|
Concept_In_Subset | ||
Contributing_Source |
FDA |
|
DEFINITION |
A first generation ethanolamine with antiinflammatory, sedative and antihistamine properties. Doxylamine competitively inhibits the histamine 1 (H1) receptor, thereby preventing the action of endogenous histamine as well as the subsequent release of pro-inflammatory mediators from basophils and mast cells. This agent acts as an inverse agonist that combines with, and stabilizes the inactive form of the H1-receptor, shifting the H1 receptor equilibrium toward the inactive state. This results in downregulation of nuclear factor-kappaB (NF-kappaB) and NF-kappaB dependent antigen presentation, chemotaxis, as well as expression of cell-adhesion molecules and pro-inflammatory cytokines. |
|
FDA_UNII_Code |
95QB77JKPL |
|
FULL_SYN |
DOXYLAMINE Doxylamine |
|
Has_Salt_Form | ||
label |
Doxylamine |
|
Legacy Concept Name |
Doxylamine |
|
Preferred_Name |
Doxylamine |
|
prefixIRI |
Thesaurus:C61738 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0013092 |
|
subClassOf |